Neuroblastom
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DIS-NEUROBLASTOMA |
|---|---|
| Art | Erkrankung |
| Aliase | Pädiatrische periphere neuroblastische Tumoresympathischer nervöser embryonaler Tumor des SystemsНейробластома |
| Status | reviewed 2026-05-20 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-NCCN-PEDIATRIC-SARCOMA |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9500/3 |
|---|---|
| icd_o_3_topography | ["C74.9", "C47", "C48"] |
| icd_10 | C74.9 |
| who_classification | WHO Endokrine Tumore 5 ed (2022): Neuroblastom — peripherer neuroblastischer Tumor sympathisch-nervöser Systemherkunft; INSS + INRG-Staging; MYCN-Verstärkung + ALK-Änderungen sind wichtige prognostische + zielbare |
Anmerkungen
COG + SIOPEN risk-stratified treatment frameworks. Anti-GD2 immuno- therapy (dinutuximab + cytokines) is high-risk standard since 2009; ch14.18/Naxitamab as alternative. Lorlatinib + crizotinib for ALK- mutant subset (cooperative-group trials). MIBG-iodine131 + lutathera therapy for MIBG-avid relapsed disease. Surveillance for syndromic predisposition carriers: abdominal US + urinary catecholamines q3-6mo to age 8 in Costello + Beckwith-Wiedemann.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.